KRAS mutations activate the critical GTP/GDP GTPase exchange protein, a molecular switch that activates various intracellular signaling pathways that regulate the proliferation and metastasis of PAAD, thereby affecting patient survival49. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.